GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vincerx Pharma Inc (OTCPK:VINC) » Definitions » Additional Paid-In Capital

VINC (Vincerx Pharma) Additional Paid-In Capital : $196.08 Mil(As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Vincerx Pharma Additional Paid-In Capital?


Vincerx Pharma's quarterly additional paid-in capital increased from Sep. 2024 ($190.19 Mil) to Dec. 2024 ($191.79 Mil) and increased from Dec. 2024 ($191.79 Mil) to Mar. 2025 ($196.08 Mil).

Vincerx Pharma's annual additional paid-in capital increased from Dec. 2022 ($166.65 Mil) to Dec. 2023 ($170.33 Mil) and increased from Dec. 2023 ($170.33 Mil) to Dec. 2024 ($191.79 Mil).


Vincerx Pharma Additional Paid-In Capital Historical Data

The historical data trend for Vincerx Pharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vincerx Pharma Additional Paid-In Capital Chart

Vincerx Pharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial 42.04 156.31 166.65 170.33 191.79

Vincerx Pharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 170.86 188.77 190.19 191.79 196.08

Vincerx Pharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Vincerx Pharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Vincerx Pharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Vincerx Pharma Business Description

Traded in Other Exchanges
N/A
Address
1825 S. Grant Street, San Mateo, CA, USA, 94402
Vincerx Pharma Inc is a clinical-stage biopharmaceutical company focused on development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. The company's activities are conducted in the United States. It focuses on developing, using, manufacturing, commercializing, sublicensing, and distributing a clinical-stage and follow-on small molecule drug program and a preclinical-stage bioconjugation/next-generation ADC platform.
Executives
Alexander A. Seelenberger officer: Chief Financial Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Raquel E. Izumi director, 10 percent owner, officer: Chief Operations Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Ahmed Md Hamdy director, 10 percent owner, officer: President and CEO 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Tom C Thomas officer: See Remarks 180 LOMA ALTRO, C/O MOCON INC, LOS GATOS CA 95030
Christopher P. Lowe director 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Laura I. Bushnell director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Sooin Hwang officer: Chief Business Officer 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Xiaoming Zhang officer: Chief Technology Officer 260 SHERIDAN AVE, SUITE 400, PALO ALTO CA 94306
Ruth E. Stevens director 260 SHERIDAN AVENUE, SUITE 400, PALO ALTO CA 94306
Garban Hermes De Jesus officer: Chief Medical Officer 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
John C. Byrd 10 percent owner 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Brian Druker director ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
John H. Lee director 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054